Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.
Launched by JEREMY KEARNS · Dec 19, 2019
Trial Information
Current as of July 09, 2025
Terminated
Keywords
ClinConnect Summary
After obtaining a signed informed consent, participating patients will be randomized by computer generated random numbers to either the control group to receive continuous Erector Spinae Plane block (in the case of thoracic surgery) or continuous Quadratus Lumborum block (in the case of abdominal surgery), or the treatment group to receive single shot Erector Spinae Plane block (in the case of thoracic surgery) or single shot Quadratus Lumborum block (in the case of abdominal surgery) with postoperative intravenous lidocaine infusion. Subjects will be randomized in a 1:1 ratio. Randomizatio...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-90 years old
- • Primary unilateral VATS or major abdominal surgery
- • BMI 20-36, weight ≥ 50kg
- • Male and Female
- • All races
- Exclusion Criteria:
- • Patient refusal
- • Inpatient status at the time of surgery
- • ASA class 4 or greater
- • Pregnancy
- • Non-English speaking or inability to participate in the study
- • Patients with coagulopathy or on therapeutic anticoagulation
- • Chronic steroid use
- • Opioid use disorder
- • Contraindication to performing any of the proposed blocks - active infection at the block site, systemic infection, allergy to local anesthetic medications
- • Patients undergoing second surgery or urgent/emergent surgery
- • Patients weighing \< 50kg
- • History of chronic pain and/or opioid tolerant
- • Anticipated requirement for patient-controlled analgesia (PCA)
- • Allergy or intolerance to any medication specified in the study protocol or postoperative pain management regimen
- • Liver disease
About Jeremy Kearns
Jeremy Kearns is a dedicated clinical trial sponsor specializing in the design, execution, and oversight of innovative research studies aimed at advancing medical knowledge and treatment options. With a strong emphasis on patient safety and ethical standards, Kearns leverages extensive experience in clinical research to collaborate with diverse stakeholders, including healthcare professionals, regulatory bodies, and research institutions. Committed to fostering scientific integrity and transparency, he ensures that each trial is conducted with rigor and precision, ultimately contributing to the development of effective therapies and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Jacques E Chelly, MD, PhD, MBA
Principal Investigator
University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials